Daraxonrasib Extends Survival in KRAS-Mutant Pancreatic Cancer Phase 3 Trial

The randomized study enrolled patients with previously untreated metastatic disease harboring KRAS mutations, which occur in over 90 percent of pancreatic adenocarcinomas. Daraxonrasib, an oral RAS(ON) inhibitor, produced objective responses in 38 percent of participants compared with 19 percent on chemotherapy, with progression-free survival of 6.8 versus 3.9 months. Grade 3 or higher adverse events occurred at similar rates, though rash and diarrhea required dose reductions in 22 percent of the experimental arm.

Prior KRAS inhibitors such as sotorasib demonstrated only modest activity in pancreatic cancer, highlighting the improved potency of this next-generation molecule. Real-world data from the SEER-Medicare registry indicate that fewer than 15 percent of patients currently receive targeted therapy at diagnosis, suggesting rapid uptake will depend on companion diagnostic availability and reimbursement pathways. Regulatory filings are expected in both the US and EU within six months.

The trial's open-label design and exclusion of patients with prior adjuvant therapy limit generalizability to the broader population. Ongoing combination studies with PD-1 inhibitors will determine whether the observed survival increment can be further extended.